Obesity➡️ worse prognosis & different biology #breastcancer. Still, BMI is only reported in 8% of 495 trials we reviewed. More research needed to study impact of BMI on treatment efficacy and toxicity🙏 ! Josephine Van Cauwenberge KarenVanBaelen OncoAlert doi.org/10.1186/s13058…

Patricia Lorusso, “We need real time utilisation of Patient Reported Outcomes to aid clinical drug development”.

Peter A. Fasching, “In the NATALEE breast cancer trial, a dose reduction of Ribociclib did not impact efficacy…” #ESMO24 METUPUK

Great talks on metastatic breast cancer oligometastatic bone, brain and leptomeningeal disease Biological rationale for local therapy of oligoprogressive disease…. #ESMO24 METUPUK

Giampaolo Bianchini sums up MBC HER2 classifications for T-Dxd; IHC 0 assessments must be re-evaluated, one in four patients with local IHC 0 are improperly denied access to a very effective treatment #ESMO24 METUPUK

Thanks a lot for the fantastic edition of the #ilcsymposium 2024 in Leuven! What an amazing community! Step by step moving together in the right direction for patients with #lobular breast cancer ELBCC Patrick WB Derksen Dr. Steffi Oesterreich Philippe Aftimos, MD  Anne Vincent-Salomon

No one is counting Metastatic Breast Cancer patients in the UK. In 2022, a National Audit of Metastatic Breast Cancer (NAoMe) was commissioned. This urgently needs to address the major issue: ‘How many of us are there?’. Our patient advocate Kirstin explains how NAoMe MUST

American Association for Cancer Research Award winning Steffi Oesterreich gives an insightful and inspirational lecture about Lobular breast cancer. LobularMoonShotProject Lobular Breast Cancer Alliance Lobular Research Elbca

I’m taking part in Our Future Health. Join the UK’s largest health research programme: ourfuturehealth.org.uk/join/1105

ESR1 Y537S and D538G mutations drive resistance to CDK4/6 inhibitors in estrogen receptor-positive breast cancer pubmed.ncbi.nlm.nih.gov/39992682/ This is an Elegant combination of real-world data and experimental data mechanistically relating ESR1mut with resistance to CDK 4/6 inhibitors.

The Darker Side of Pink Campaign is coming to Oxford! Come see the interactive exhibition in Oxford at the Westgate Library, next to the Westgate Shopping centre in Oxford. The exhibition is there from 4th March to 31st March 2025. If you are attending at any point, we would

Update from the #EMBER3 trial based on subgroup analysis 👀 at the curve in patients with co-mutated #ESR1 and #PIK3CA ESMO - Eur. Oncology #ESMObreast25

Proffered paper session at #ESMOBreast25 with Nadia Harbeck,MD PhD presenting the first results of #ADAPTcycle trial showing preliminary evidence on the possibility to avoid #chemotherapy by using CDK4/6i + endocrine therapy in early #BreastCancer ESMO - Eur. Oncology #ESMOAmbassadors OncoAlert

🔹 1L: AI or Fulv + CDK4/6i 🔹 2L:  • PI3K & ESR1 wt: Fulv + Everolimus / Abemaciclib  • ESR1 mut: Elacestrant  • PI3K mut: Fulv + Alpelisib / Capivasertib 🔹 3L+: Options incl. chemo, Elacestrant, Olaparib, T-DXd 🔹 4L+: SG, DATO-DXd, biomarkers Sara Tolaney OncoDaily ESMO - Eur. Oncology

In talking about whole brain radiation in MBC brain mets Christine Hodgdon reminds the panel and audience that WBR, in addition to causing cognitive deficits, also has the “side effect” of excluding people from virtually all clinical trials. #ESMOBreast25

Christine Hodgdon also addresses patient concerns about brain biopsy - especially after attending an earlier session which presented data that biopsy or surgery of a brain met increases the risk of LMD. And kudos to Nancy Lin, MD for getting the patient perspective 1st! #ESMOBreast25

Nick Turner sums up what we learned here about MBC, starting with EMBER3 #ESMOBreast25

Not forgetting those who are triple positive, adding ET and a CDK4/6 to HER2 targeted therapy provides benefit over just antiHER2 + ET.

In California this week for NBCC’s Project LEAD—an intensive training in breast cancer science, clinical trials & advocacy. Grateful for the scholarship & excited to deepen my impact for patients everywhere. #ProjectLEAD #BreastCancerAdvocacy #NBCC #METUPUK

Very big news out today-- adjuvant abemaciclib improves overall survival in high-risk ER+ breast cancer at ~7 yrs of f/u! Showing OS benefit in this setting is not easy & nice to see what an incredible impact adj cdk4/6i can have for our patients! prnewswire.com/news-releases/…